Azitra, Inc. - חוב לטווח קצר של החברה AZTR

Azitra, Inc. (AZTR) is developing innovative therapies for skin pathologies through genetic modification, with financial stability contingent upon the success of its research, while debt stands at 0.00. The company is currently conducting independent testing of new drugs, limiting itself only to narrow patent alliances. Commitment to ESG principles and laboratory eco-safety are highlighted in the share price trend shown in the chart below.

This metric captures total liabilities with a maturity of up to one year, reflecting liquidity sensitivity to operational cash flows. The current value of 0.00 demonstrates a level of debt load that is critical for Azitra, Inc. (AZTR) while awaiting insurance payments for genetically modified drugs; therefore, the risk of working capital deficits should be assessed via the current debt obligations chart.